SLC5A2 and type 2 diabetes mellitus: However, a prospective multicenter study found that SGLT2 inhibitors might also significantly modulate the cardiac autonomic neuropathy dysfunction in type 2 diabetes mellitus patients with vasovagal syncope leading to a reduction of vasovagal syncope recurrence in these patients (Sardu et al., 2022).